Welcome to the SCW blog, where we share practical insights on building faster, more resilient, and more compliant supply chains in life sciences and other regulated industries. Here, we translate real transformation work into clear takeaways, from strategy to execution, so teams can move from “where do we start?” to measurable impact.
Compliance maturity is measured by the consistency and control of day-to-day operations long after go-live, not by the success of the implementation itself. This is why EPCIS 2.0 matters.
NMVO country guide for MAHs: compare alert timelines, understand EAMS workflows, and standardize investigations across Europe with audit-ready playbooks.
When an EMVS alert traces back to a CMO, investigation speed depends on the coordination model you built before the alert arrived. Here’s how to design it.
Digital Factory maturity has moved well past the stage of being a strategic aspiration. In 2026, it is an operational imperative, the backbone of a resilient pharma supply chain, one that determines whether your site can release products faster, sustain compliance under regulatory scrutiny, and scale without the kind of constant firefighting that quietly erodes capacity and morale.
The pharma supply chain is not a forgiving environment for shortcuts. The processes are complex, the regulatory exposure is real, and the downstream impact of poor data or unclear ownership is significant. Autonomous actions, at any meaningful scale, require you to have already solved for that complexity, not planned to solve it later.
Reducing alerts is often framed as an execution problem, how quickly can teams investigate and close them? But in practice, the real issue is different. It is not the volume of alerts, but the quality of those alerts.
The era of the “smart pharma factory” is finally bridging this divide. By integrating digital manufacturing systems, specifically the Manufacturing Execution System (MES), with the broader pharma supply chain, companies are unlocking live visibility and unprecedented responsiveness.
The critical detail most teams miss is that AMS access is OBP-based, not MAH-based and as defined by EMVO, OBPs can create users and structure them into teams to control alert visibility by market. The practical implication is that onboarding success depends on how entities, teams, market coverage, and ownership are designed, not simply on system access.
The European Medicines Verification System (EMVS) only works at scale when alerts are handled quickly, consistently, and with high-quality data. A single alert at dispensing can trigger quarantine procedures, investigations, and communication with national verification organizations. When this happens across hundreds of SKUs, multiple CMOs, and many European markets, the operational workload grows rapidly.
